DuP 105

Class: Oxazolidinone

Spectrum of activity:	Gram-negative
Details of activity:	Active against S. aureus, with equal activity against MRSA as MSSA.
Institute where first reported:	DuPont (Bristol-Myers Squibb, UK)
Year first mentioned:	1987
Highest developmental phase:	Phase 1
Development status:	Inactive
Reason Dropped:	Less active that DuP 721 (4 fold) and possible toxicity issues (1).

Chemical structure(s):
Canonical SMILES:	CC(=O)NC[C@H]1CN(C2=CC=C(C=C2)S(=O)C)C(=O)O1
Isomeric SMILES:	CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC=C(C=C2)S(=O)C
InChI:	InChI=1S/C13H16N2O4S/c1-9(16)14-7-11-8-15(13(17)19-11)10-3-5-12(6-4-10)20(2)18/h3-6,11H,7-8H2,1-2H3,(H,14,16)/t11-,20?/m0/s1
InChI Key:	RYTTWOVTZKVWTO-ZOZMEPSFSA-N
Structure link:	https://pubchem.ncbi.nlm.nih.gov/compound/57141

External links:
Guide to Pharmacology:	Dup-105
Citations:	https://books.google.co.uk/books?id=_HFitfA4OcUC&pg=PA178&lpg=PA178&dq=DuP+721+phase+1&source=bl&ots=inRvcfCNtS&sig=1Igumvoss_5XbM6KZsGxdUysR4s&hl=en&sa=X&ei=Ind1VaHmOoX_UIKzgOAJ&ved=0CCEQ6AEwAA#v=onepage&q=DuP%20721%20phase%201&f=false http://www.ncbi.nlm.nih.gov/pmc/articles/PMC172119/pdf/aac00080-0190.pdf